Epidemiology & economics

Bacterial resistance costs French hospitals up to 290 million Euros per year

Original uploader was Philippinjl at fr.wikipedia, Testbaci, CC BY-SA 2.5

A team of researchers from Versailles Saint-Quentin-en-Yvelines University (UVSQ), Inserm and Pasteur Institute (Unité Mixte de Recherche 1181 Biostatistique, biomathématique, pharmacoépidémiologie et maladies infectieuses – B2PHI) has been able to provide for the first time an accurate estimate of both the incidence (annual number of new cases) and added direct cost of infections due to antibiotic-resistant bacteria in patients hospitalised in French hospitals during 2015 and 2016.

The results of these studies, conducted by Mehdi Touat and by Marion Opatowski under the direction of Laurence Watier, in collaboration with Prof. Christian Brun-Buisson within the research group conducted by Prof. Didier Guillemot, appeared respectively in Applied Health Economics and Health Policy and in Epidemiology & Infection.

Recommended article

Photo

Nosocomial infections

Global-PPS: Hospital antibiotic resistance study tops 200k

BioMérieux and the Laboratory of Medical Microbiology at the University of Antwerp announced at ECCMID (European Congress of Clinical Microbiology & Infectious Diseases) the 2018 results of the Global Point Prevalence Survey (GLOBAL-PPS), a study of antibiotic use and antimicrobial resistance (AMR) in hospitals around the world. Since its launch in 2015, this survey has been conducted in…

In 2016, close to 140 000 new cases of infections due to antibiotic-resistant bacteria were identified, accounting for 12% of all bacterial infections needing hospitalisation. Infections of the urinary tract, of the respiratory tract and intra-abdominal infections represented about two-thirds of such cases. Most antibiotic-resistant infections were caused by third-generation cephalosporin-resistant E.coli, meticillin-resistant S.aureus (MRSA) and P.areuginosa. Compared to infections caused by antibiotic-susceptible bacteria, infections due to antibiotic-resistant bacteria were associated with a 20% higher in-hospital death rate.

The researchers estimated that, from the payer’s perspective, the mean added cost of hospital stay associated with infection due to resistant bacteria amounted to € 1100, leading to an overall population-based estimate of up to € 290 million in French hospitals.

Based on diagnosis coding information routinely collected during each and every hospital stay in France, and using data collected on over 10 millions annual hospital stays, these studies are based on data of outstanding comprehensiveness (French Health Data System). Initiated 3 years ago, these studies were made possible through grants from the French Ministry of Health and the social security system (Assurance Maladie).

The algorithms created for these studies will be made publicly available. This will now make it possible to quickly carry out the analyses for the following years and the years to come.


Source: Institut Pasteur

05.05.2019

Read all latest stories

Related articles

Photo

Hospital hygiene

Will resistant bacteria be the end of alcohol hand sanitizers?

Alcohol-based hand sanitisers have been a mainstay in hospital hygiene for decades. But now, strains of antibiotic-resistant bacteria show signs of overcoming these handwashing agents as well. Does…

Photo

Survival specialists

Systems biology of antibiotics

Bacteria have fascinating properties. They adapt excellently to their respective environment, and they existed long before humans. Their toughness has led to the fact that bacteria have successfully…

Photo

Survival of the fittest

How bacteria can adapt to resist antibiotic treatment

In a joint collaboration, researchers from Denmark and Switzerland have shown that bacteria produce a specific stress molecule, divide more slowly, and thus save energy when they are exposed to…

Related products

Eppendorf - Mastercycler nexus X2

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG
SARSTEDT - Low DNA Binding Micro Tubes

Research use only (RUO)

SARSTEDT - Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH